RELMADA THERAPEUTICS INC (OTCMKTS:RLMD) Sellers Strengthened By 2475.76% Their Shorts As Of Mar 11, 2019

Relmada Therapeutics, Inc. (OTCMKTS:RLMD) Corporate Logo Change of 2475.76% for RELMADA THERAPEUTICS INC (OTCMKTS:RLMD)’s shares shorted was showed. FINRA issued shares shorted of RLMD’s total 85,000 shares. The up change of 2475.76% from 3,300 shares was reported. Former RLMD’s position will need 2 days to recover. It has 54,900 average volume.

RLMD touched $1.65 during the last trading session after $0.1 change.Relmada Therapeutics, Inc. has volume of 3,420 shares. Since March 11, 2018 RLMD has 0.00% and is . RLMD underperformed the S&P500 by 4.37%.

Relmada Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing drugs to treat central nervous system diseases, primarily depression and chronic pain in the United States.The firm is valued at $49.94 million. The Company’s lead product candidate, d-Methadone, is being developed as a rapidly acting, oral agent for the treatment of depression, neuropathic pain, and/or other potential CNS pathological conditions.Currently it has negative earnings. The firm is also developing include LevoCap ER, an extended release, abuse deterrent, proprietary formulation of the opioid analgesic levorphanol for the management of pain; BuTab ER, a formulation of oral, modified release buprenorphine for chronic pain and opioid dependence indications; and MepiGel, a proprietary topical dosage form of the local anesthetic mepivacaine for the treatment of painful peripheral neuropathies, such as painful diabetic neuropathy, postherpetic neuralgia, and painful HIV-associated neuropathy.

For more Relmada Therapeutics, Inc. (OTCMKTS:RLMD) news released recently go to: , , , or . The titles are as follows: “If You Like Zogenix, You’ll Love This Stock : Focused Small Caps – SmallCap Network” released on October 23, 2015, “A Controlled-Release Painkiller Pipeline With Depth AND Breadth : Small Cap Diligence – SmallCap Network” on December 02, 2015, “Relmada nabs expanded rights to CNS candidate dextromethadone; shares ahead 8% – Seeking Alpha” with a publish date: January 17, 2018, “Relmada Therapeutics provides enrollment update in Phase 2 study of REL-1017 – Seeking Alpha” and the last “Key events next week – healthcare – Seeking Alpha” with publication date: December 07, 2018.

Click Here to Continue...

Add a Comment

Your email address will not be published. Required fields are marked *